Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
Dual Role of Rh(III) Catalyst Enables Regioselective Halogenation of (Electron-Rich) Heterocycles
作者:Nils Schröder、Fabian Lied、Frank Glorius
DOI:10.1021/jacs.5b00283
日期:2015.2.4
The Rh(III)-catalyzed selective bromination and iodination of electron-rich heterocycles is reported. Kinetic investigations show that Rh plays a dual role in the bromination, catalyzing the directed halogenation and preventing the inherent halogenation of these substrates. As a result, this method gives highly selective access to valuable halogenated heterocycles with regiochemistry complementary
Directing Group-Assisted Copper(II)-Catalyzed<i>ortho</i>-Carbonylation to Benzamide using 2,2′-Azobisisobutyronitrile (AIBN)
作者:Bhuttu Khan、Afsar Ali Khan、Ruchir Kant、Dipankar Koley
DOI:10.1002/adsc.201600664
日期:2016.12.7
been developed using 2,2′‐azobisisobutyronitrile (AIBN) as traceless cyanating agent. The non‐toxic and readily available AIBN was used for the carbonylative cyclization of benzamides via copper catalysis. The method is also applicable for the regioselective cyanation of furan, benzofuran, thiophene, benzothiophene, and pyrrole carboxamide derivatives.
Benzothiazole derivatives with activity as adenosine receptor ligands
申请人:——
公开号:US20020045615A1
公开(公告)日:2002-04-18
The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.